alpha-甲基-3,4-二羟基苯丙酸 | 53832-94-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: alpha-甲基-3,4-二羟基苯丙酸
• 英文名称: 3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
• 英文别名: 2-Methyl-3,4-dihydroxyphenylpropionic Acid
• CAS: 53832-94-3
• 化学式: C₁₀H₁₂O₄
• mdl: MFCD03428563
• 分子量: 196.203
• InChiKey: GIIOASILGOFVPI-UHFFFAOYSA-N

物化性质

• 熔点：
  110-112°C
• 沸点：
  411.4±30.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)
• 溶解度：
  二氯甲烷（轻微、加热、超声处理）、DMSO（轻微）、甲醇（轻微)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2918290000

反应信息

• 作为产物：
  描述：

  S(-)-carbidopa 在 mushroom tyrosinase, specifi activity 2956 U/mg 、 氧气 作用下， 以 1,2,3,4-四氢萘 为溶剂， 反应 0.5h， 生成 卡比多巴杂质 、 alpha-甲基-3,4-二羟基苯丙酸
  参考文献：
  名称：

  Oxidation of carbidopa by tyrosinase and its effect on murine melanoma

  摘要：

  Oxidation of the anti-Parkinsonian agent carbidopa by tyrosinase was investigated. The products of this reaction were identified as 3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid and 6,7-dihydroxy-3-methylcinnoline. These results demonstrate that after oxidation of the catechol moiety to an o-quinone either a redox exchange with the hydrazine group or a cyclization reaction occur. The cyclization product underwent additional oxidation reactions leading to aromatization. The cyclization reaction is undesired in the case of hydrazine-containing anti-melanoma prodrugs and will have to be taken into account in designing such compounds. Carbidopa was tested against B16(F10) melanoma cells in culture and showed cytotoxicity significantly higher than either of its oxidation products and L-dopa. This effect, however, was not specific to this cell line. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.002

文献信息

• [EN] INJECTABLE HYDROGELS AND USES THEREOF<br/>[FR] HYDROGELS INJECTABLES ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV STRASBOURG

  公开号：WO2018134268A1

  公开（公告）日：2018-07-26

  The invention relates to a hydrogel, in particular degradable or non degradable, comprising monomers of formula (I) and organosilica particles or porous silicon particles covalently bound thereto, optionally with non covalently bound organosilica and/or silicon particles mixed therewith, in particular degradable organosilica nanoparticles or core-shell nanocapsules; pharmaceutical, veterinary or cosmetic compositions thereof; and uses thereof as a medicament. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.

  该发明涉及一种水凝胶，特别是可降解或不可降解的水凝胶，包括式(I)的单体和共价结合在一起的有机硅颗粒或多孔硅颗粒，可选地与非共价结合的有机硅和/或硅颗粒混合在一起，特别是可降解的有机硅纳米颗粒或核壳纳米胶囊；以及其制备的药用、兽医或化妆品组合物；以及作为药物的用途。该发明在治疗和诊断医疗技术领域以及化妆品和兽医技术领域中找到应用。
• Interference of carbidopa and other catechols with reactions catalyzed by peroxidases
  作者：Beata Gąsowska-Bajger、Yuki Nishigaya、Krystyna Hirsz-Wiktorzak、Anna Rybczyńska、Toshimasa Yamazaki、Hubert Wojtasek

  DOI：10.1016/j.bbagen.2018.04.007

  日期：2018.7

  4-aminoantipyrine/phenol in the presence of carbidopa, an anti-Parkinsonian drug, and other catechols, including l-dopa, were monitored spectrophotometrically and by measuring hydrogen peroxide consumption. RESULTS Chromophore formation in all three enzyme/substrate systems was blocked in the presence of carbidopa and other catechols. However, the rates of hydrogen peroxide consumption were not much affected

  背景技术已经报道了许多化合物，包括抗坏血酸，儿茶酚胺，类黄酮，对二酚和肼衍生物会干扰基于过氧化物酶的医学诊断测试（Trinder反应），但是尚未完全阐明这些作用的机理。方法在存在卡比多巴，抗帕金森病药物和其他邻苯二酚（包括左旋多巴）的存在下，通过分光光度法和通过测量来监测牛骨髓过氧化物酶与邻联苯胺苷，牛乳过氧化物酶与ABTS的辣根过氧化物酶与4-氨基安替比林/苯酚的反应消耗过氧化氢。结果在存在卡比多巴和其他邻苯二酚的情况下，所有三种酶/底物系统中的发色团形成均被阻止。但是，过氧化氢的消耗速率没有受到太大的影响。不可逆的酶抑制作用也很小。结论测试的化合物减少了模型底物的氧化产物或中间体，从而防止了生色团的形成。这种干扰可能会影响对卡比多巴和左旋多巴治疗的帕金森氏病患者的诊断测试结果的解释。一般意义该机制可预测基于过氧化物酶的其他化合物（包括药物和天然产物）的诊断测试中的干扰。
• Dopa decarboxylase inhibitor compositions
  申请人：NeuroDerm, Ltd.

  公开号：US10022320B2

  公开（公告）日：2018-07-17

  Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

  本文公开了含有卡比多巴和可选左旋多巴、精氨酸及其他成分的制剂，这些制剂中的杂质和毒素，特别是降解产物的含量较低。本文还公开了使用此类制剂治疗与多巴胺或多巴胺能神经元丧失有关的疾病或病症的方法、制造此类制剂的方法以及包含此类制剂的试剂盒。
• Levodopa and carbidopa intestinal gel and methods of use
  申请人：AbbVie, Inc.

  公开号：US10117843B2

  公开（公告）日：2018-11-06

  The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

  本公开涉及(a)一种改进的药物组合物，其中包含一种左旋多巴活性剂和一种卡比多巴活性剂；(b)生产该药物组合物的方法；(c)治疗帕金森病及相关病症的方法，包括向帕金森病患者施用该药物组合物。
• DOPA decarboxylase inhibitor compositions
  申请人：NeuroDerm, Ltd.

  公开号：US10258585B2

  公开（公告）日：2019-04-16

  Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

  本文公开了含有卡比多巴和可选左旋多巴、精氨酸及其他成分的制剂，这些制剂中的杂质和毒素，特别是降解产物的含量较低。本文还公开了使用此类制剂治疗与多巴胺或多巴胺能神经元丧失有关的疾病或病症的方法、制造此类制剂的方法以及包含此类制剂的试剂盒。